Accout Center s.r.o.

Sahy 10 trials 3 recruiting

10 Registered trials

3 Currently recruiting

Organisation

Accout Center s.r.o.

Location

Sahy, Slovakia

Identifier

ORG-100047230

Address

Hviezdoslavova 402/19, 936 01, Slovakia

Departments

Accout Center s.r.o.
Accout Center, s.r.o.
Gastoenterologicka ambulancia
Gastroenterologicka ambulancia
NA

Clinical trials at this site (10)

Search interface

A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown

2025-523766-25-00 Ulcerative colitis 5
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn’s Disease (CD) Recruiting

2024-518914-18-00 Moderate to Severely Active Ulcerative Colitis & Modera 4 2025-08-27
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting

2023-508234-34-00 Crohn's disease 4 2025-01-27
A Phase 2b Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease Recruiting

2023-506704-14-00 Moderately to Severely Active Crohn's Disease 4 2024-09-04
A Study to Assess the Effectiveness and Safety of RO7790121 for Induction Therapy in Participants with Moderately to Severely Active Ulcerat… Ended

2024-513015-27-00 Moderately to Severely Active Ulcerative Colitis (UC) 5 2025-01-09
A Phase 2a/b study of the efficacy and safety of subcutaneous amlitelimab in adults with non-responsive celiac disease Ended

2024-511213-38-00 Coeliac disease 4 2024-10-15
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended

2023-506769-67-00 Moderate to Severely Active Ulcerative Colitis 4 2024-09-04
A Study to Investigate Bowel Urgency in Adults with Moderately to Severely Active Ulcerative Colitis Treated with Mirikizumab Ended

2022-502393-16-00 Moderately to Severely Active Ulcerative Colitis 5 2023-09-06
ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended

2022-500536-11-01 Moderately to severely active ulcerative colitis 5 2023-06-08
VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Ended

2023-509233-39-00 Moderately to Severely Active Ulcerative Colitis 4 2022-01-20